Research programme: TGF-beta RI kinase inhibitors - SciosAlternative Names: SX-007; TGF-beta RI kinase inhibitors; TGF-beta RI kinase inhibitors research programme - Scios
Latest Information Update: 16 Jul 2016
At a glance
- Originator Scios
- Mechanism of Action Transforming growth factor beta1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 09 May 2005 Preclinical trials in Glioblastoma in USA (unspecified route)